📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-22 14:50
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
Shukra Pharma Approves Rebranding to 'Shukra Medtech' and Expands MOA into Medical Devices
Shukra Pharmaceuticals Ltd's Board has approved changing the company's name to 'Shukra Medtech Limited', subject to regulatory and shareholder approvals. The company is altering its Memorandum of Association (MOA) to expand its main objects into medical devices, surgical robotics, AI-based healthcare technologies, and MedTech parks. Approval will be sought via postal ballot. Additionally, the 33rd Annual General Meeting (AGM) is scheduled for September 25, 2026.
Confidence: HIGH
What changedThe Board approved the rebranding to Shukra Medtech Limited and expanded the object clause of the MOA into medical devices and healthcare technologies.
Why it mattersSignals a strategic intent to diversify beyond traditional pharma into higher-tech medical devices, surgical systems, and digital health platforms.
Board meeting date: 22nd August, 2026AGM date: 25th September, 2026Book closure start date: 19th September, 2026Book closure end date: 25th September, 2026
📅 Short termShareholders will vote on the proposed MOA amendments and name reservation via postal ballot over the coming weeks.
📈 Long termEnables the company to structurally pivot and build capabilities in the medical equipment and AI healthcare domain, pending commercial execution.
⚠ Risk flags
- Execution risk entering complex MedTech and robotics segments without prior disclosed track record
- Subject to shareholder and Ministry of Corporate Affairs (CRC) approvals
Key Highlights
Board approved name change from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'
MOA Clause III(A) amended to add 6 sub-clauses covering medical devices, surgical robotics, AI healthcare, and MedTech parks
Shareholder approval to be sought via postal ballot alongside necessary approvals from MCA/CRC
33rd Annual General Meeting scheduled for September 25, 2026, via Video Conferencing
Register of Members and Share Transfer Books to remain closed from September 19, 2026 to September 25, 2026
👀 What to Watch
Track the upcoming postal ballot voting results, MCA/ROC approval for the name change, and subsequent disclosures on concrete MedTech business investments or partnerships.
Shukra Pharmaceuticals to Rebrand as Shukra Medtech; Expands into Medical Technology Sector
The Board of Shukra Pharmaceuticals has approved a proposal to change the company's name to 'Shukra Medtech Limited' and expand its business objects to include the Medical Technology (MedTech) sector. This strategic pivot allows the company to engage in R&D, manufacturing, and distribution of medical devices and equipment alongside its existing pharmaceutical business. Financially, the company reported a strong June 2026 quarter with a net profit of Rs 12.96 Cr on revenue of Rs 23.52 Cr. The move is subject to shareholder and regulatory approvals.
Confidence: HIGH
What changedThe company is transitioning from a pure-play pharmaceutical firm to a broader healthcare and medical technology entity by altering its Memorandum of Association.
Why it mattersThis diversification into MedTech could provide new growth avenues and potentially higher valuation multiples, though it requires different regulatory expertise and manufacturing capabilities.
June 2026 Revenue: Rs 23.52 CrJune 2026 Net Profit: Rs 12.96 CrNet Worth: Rs 90 CrTotal Debt: Rs 5 CrDebt-to-Equity Ratio: 0.06
📅 Short termThe announcement is primarily administrative in the short term; market reaction will likely be neutral until concrete MedTech projects are announced.
📈 Long termRepresents a structural shift in the business model; long-term success depends on the company's ability to navigate the specialized regulatory and technical landscape of medical devices.
⚠ Risk flags
- Execution risk in a new business segment
- Regulatory hurdles for medical device certifications
- Potential for high initial R&D and capital expenditure
Key Highlights
Board approved name change to 'Shukra Medtech Limited' on August 14, 2026
Expansion of Main Objects to include MedTech R&D, manufacturing, and distribution
June 2026 quarterly revenue reported at Rs 23.52 Cr with Rs 12.95 Cr net profit
Company maintains a low debt profile of Rs 5 Cr against a net worth of Rs 90 Cr
Promoter holding remains stable at 50.95% as of June 2026
👀 What to Watch
Monitor shareholder approval for the name change and watch for future disclosures regarding specific capital expenditure or product pipelines in the MedTech segment.
37% ROCE Shukra Pharma to Rebrand as Shukra Medtech; Expands into Medical Technology
Shukra Pharmaceuticals' Board has approved a proposal to change the company's name to 'Shukra Medtech Limited' and expand its business objects to include the Medical Technology (MedTech) sector. This strategic shift aims to include R&D, manufacturing, and distribution of medical devices and systems alongside its existing pharmaceutical business. Financially, the company maintains a strong profile with a net worth of Rs 90 Cr and a high ROCE of 37.0%. The expansion is intended to create long-term growth opportunities, pending shareholder and regulatory approvals.
Confidence: HIGH
What changedThe company is transitioning from a pure-play pharmaceutical firm to a broader healthcare and medical technology entity, including a formal name change.
Why it mattersThis pivot allows the company to diversify into the MedTech sector, which may offer different growth trajectories and valuation multiples compared to its core pharma business.
Quarterly Revenue (Jun 2026): Rs 23.52 CrQuarterly PAT (Jun 2026): Rs 12.96 CrNet Worth: Rs 90 CrDebt-to-Equity: 0.06Promoter Holding: 51.0%
📅 Short termNeutral to slightly positive sentiment as the market evaluates the strategic shift; focus will be on the regulatory and shareholder approval process.
📈 Long termPotentially significant if the company successfully scales the MedTech business, leveraging its existing high ROCE and low debt profile.
⚠ Risk flags
- Execution risk in a new business vertical
- Regulatory hurdles for medical devices
- Lack of specific capex details for the expansion
Key Highlights
Board approval granted on August 14, 2026, for name change and object expansion.
New business scope covers development, manufacturing, and marketing of MedTech products.
Company reported a quarterly revenue of Rs 23.52 Cr for the period ending June 2026.
Net profit for the same quarter stood at Rs 12.96 Cr, reflecting high operational efficiency.
👀 What to Watch
Monitor shareholder voting results and subsequent announcements regarding specific MedTech product launches or capital expenditure plans for this new segment.
Shukra Pharmaceuticals Lists on NSE Main Board Effective August 14, 2026
Shukra Pharmaceuticals has successfully listed its equity shares on the National Stock Exchange (NSE) Main Board, effective August 14, 2026. The company, which was previously only listed on the BSE, will now be dual-listed under the symbol SHUKRAPHAR. The base reference price for the NSE debut was determined by the closing price on the BSE as of August 13, 2026. This move is strategically aimed at enhancing share liquidity and expanding the company's investor base.
Confidence: HIGH
What changedThe company's equity shares are now admitted to dealings on the National Stock Exchange (NSE) in addition to the BSE.
Why it mattersListing on the NSE, India's largest exchange by volume, typically improves price discovery, increases visibility among institutional investors, and provides better liquidity for retail shareholders.
NSE Listing Date: August 14, 2026Net Worth: Rs 90 CrDebt: Rs 5 CrJun 2026 Quarterly Revenue: Rs 23.52 Cr
📅 Short termExpect a potential increase in trading volume and minor price volatility as the stock integrates into the NSE trading system.
📈 Long termStructural positive for the company's capital market profile, potentially leading to better valuation multiples over time due to increased accessibility.
Key Highlights
Commencement of trading on NSE Main Board effective August 14, 2026
Dual-listing status maintained with existing BSE listing (Scrip Code: 531351)
Base reference price for NSE trading set based on BSE closing price of August 13, 2026
Company reported a Net Worth of Rs 90 Cr and a low Debt of Rs 5 Cr as per latest context
👀 What to Watch
Monitor the shift in trading volumes from BSE to NSE to gauge liquidity improvements. This is a structural capital market update and does not impact the underlying pharmaceutical manufacturing operations.
Shukra Pharmaceuticals Lists on NSE Main Board; Trading Commences August 14, 2026
Shukra Pharmaceuticals has successfully completed its direct listing on the National Stock Exchange (NSE) Main Board, with trading beginning August 14, 2026. The company will now be dual-listed on both the BSE and NSE, a move intended to enhance stock liquidity and attract institutional investors. This transition follows a strong financial performance in the June 2026 quarter, where the company reported a PAT of ₹12.96 crore on revenue of ₹23.52 crore. The base reference price for NSE trading was set based on the BSE closing price from August 13, 2026.
Confidence: HIGH
What changedThe company has transitioned from being solely listed on the BSE to a dual-listing on both the BSE and the NSE Main Board.
Why it mattersListing on the NSE, India's largest exchange by volume, typically increases a company's visibility to institutional investors and improves the ease of entry and exit for retail shareholders through better liquidity.
NSE Listing Date: August 14, 2026Jun 2026 Revenue: ₹23.52 crJun 2026 PAT: ₹12.96 crDebt-to-Equity Ratio: 0.06Promoter Holding: 50.95%
📅 Short termExpect increased trading activity and potential price discovery as the stock becomes accessible to a wider pool of investors on the NSE platform.
📈 Long termThe dual-listing is a structural positive that can lead to better valuation multiples over time if the company maintains its high ROCE (37%) and operational growth.
Key Highlights
Commenced trading on the NSE Main Board on August 14, 2026, under the symbol SHUKRAPHAR
Reported a high operating profit of ₹19.14 crore for the quarter ended June 2026
Maintains a strong balance sheet with a low Debt-to-Equity ratio of 0.06 and a Net Worth of ₹90 crore
Promoter holding remains stable at 50.95% as of the June 2026 quarter
The company operates cGMP compliant facilities for tablets, capsules, and liquid injections
👀 What to Watch
Monitor the shift in trading volumes from BSE to NSE to assess liquidity improvements. Investors should also watch for any increase in institutional participation in future shareholding patterns.
₹15.03 Cr Q1 PAT: Shukra Pharmaceuticals Reports 336% YoY Revenue Surge
Shukra Pharmaceuticals reported a robust Q1 FY27 (ending June 2026) with revenue from operations jumping 336% YoY to ₹23.52 Cr from ₹5.39 Cr. Net profit surged to ₹15.03 Cr, a massive turnaround from the ₹1.73 Cr loss in the preceding March 2026 quarter and a significant increase from ₹1.03 Cr in Q1 FY26. The quarterly profit alone represents approximately 68% of the company's total TTM PAT of ₹22 Cr. While the Pharmaceutical segment drove all revenue, the MedTech segment, effective from October 2025, reported zero revenue for the quarter.
Confidence: HIGH
What changedThe company has achieved a massive scale-up in its pharmaceutical operations, reversing a loss-making trend from the previous quarter (March 2026).
Why it mattersThe quarterly revenue is already 41% of the total TTM revenue, suggesting a potential structural shift in the company's growth trajectory and earnings power.
Revenue (Q1 FY27): ₹23.52 CrNet Profit (Q1 FY27): ₹15.03 CrYoY Revenue Growth: 336%Q1 PAT vs TTM PAT: 68.3%Q1 Revenue vs TTM Revenue: 41.2%
📅 Short termThe stock is likely to react positively to the sharp turnaround in profitability and the substantial YoY growth in the top line.
📈 Long termIf the company maintains this quarterly run rate, it could significantly exceed its FY26 performance; however, the lack of revenue in the MedTech segment remains a point of observation.
⚠ Risk flags
- High segment concentration in Pharmaceuticals
- Sustainability of 84% PBT margins
- Zero revenue from the MedTech segment
Key Highlights
Revenue from operations increased 336% YoY to ₹23.52 Cr from ₹5.39 Cr.
Net profit reached ₹15.03 Cr, representing a 1,360% increase over the ₹1.03 Cr reported in Q1 FY26.
Basic and Diluted EPS rose to ₹0.34 from ₹0.02 in the same quarter last year.
Total expenses were managed at ₹3.82 Cr, resulting in an exceptionally high Profit Before Tax margin of ~84%.
Pharmaceutical segment revenue (including other income) stood at ₹24.06 Cr.
👀 What to Watch
Investors should monitor the sustainability of these high operating margins and watch for the first signs of revenue generation from the newly formed MedTech segment.
₹15.03 Cr PAT: Shukra Pharmaceuticals Reports 336% YoY Revenue Growth in Q1 FY27
Shukra Pharmaceuticals reported a significant turnaround in Q1 FY27, with revenue from operations surging 336% YoY to ₹23.52 Cr compared to ₹5.39 Cr in the same quarter last year. Net profit reached ₹15.03 Cr, a sharp recovery from the ₹1.73 Cr loss reported in the immediate previous quarter (Q4 FY26). The company's quarterly revenue alone accounts for approximately 41% of its total TTM revenue of ₹57 Cr. While the Pharmaceutical segment drove all revenue, the MedTech segment remains pre-revenue but holds ₹11.55 Cr in assets.
Confidence: HIGH
What changedThe company transitioned from a loss-making quarter (Q4 FY26) to its highest quarterly profit in recent history, with a massive jump in top-line execution.
Why it mattersThe scale of revenue in Q1 (₹23.52 Cr) relative to the full-year FY26 revenue (₹57 Cr) suggests the company is on a significantly higher growth trajectory, which could lead to a valuation re-rating if sustained.
Q1 Revenue from Operations: ₹23.52 CrQ1 Net Profit: ₹15.03 CrYoY Revenue Growth: 336%Q1 Revenue vs TTM Revenue: 41.2%MedTech Segment Assets: ₹11.55 Cr
📅 Short termThe stock is likely to react positively to the sharp turnaround in profitability and the substantial YoY and QoQ revenue growth.
📈 Long termLong-term value depends on the company's ability to maintain these high operating margins and successfully scale the newly formed MedTech segment.
⚠ Risk flags
- Historical volatility in quarterly earnings
- High P/E ratio of 81.8
- Concentration of revenue in a single segment
Key Highlights
Revenue from operations increased 336% YoY to ₹23.52 Cr from ₹5.39 Cr.
Net profit stood at ₹15.03 Cr, recovering from a loss of ₹1.73 Cr in Q4 FY26.
Earnings Per Share (EPS) improved to ₹0.34 for the quarter from ₹0.02 YoY.
Pharmaceutical segment profit before tax and interest reached ₹20.67 Cr.
MedTech segment assets are recorded at ₹11.55 Cr, indicating future business potential despite zero current revenue.
👀 What to Watch
Investors should monitor the sustainability of these high margins and whether the revenue jump is due to recurring orders or one-off contracts. Watch for any updates regarding the commercialization of the MedTech segment.
